激素释放性荷尔蒙受体对抗剂 释放性荷尔蒙受体对抗剂
1Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Centre, PO Box 7057, 1007MB, Amsterdam, Netherlands.
新的GnRH抗剂立即阻断性腺激素释放激素 (GnRH) 的作用,为辅助生殖和荷尔蒙依赖性疾病提供了有效的替代方案. 这些抗剂在减少治疗持续时间和激素使用方面表现有前途.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脉动性GnRH调节垂体LH和FSH分泌,控制生殖腺功能.
- GnRH阻塞用于辅助生殖和治疗性激素依赖性疾病.
- 传统方法包括GnRH激素对抗剂脱敏,但GnRH对抗剂提供了即时的阻断.
研究的目的:
- 评估新开发的GnRH受体对抗剂的临床效用和疗效.
- 在各种临床应用中,将GnRH抗剂与现有的GnRH激动剂疗法进行比较.
主要方法:
- 对GnRH抗剂的临床数据的审查.
- 在辅助生殖和前列腺癌中,GnRH对抗剂和激动剂之间的治疗结果的比较.
主要成果:
- 在辅助生殖中,GnRH抗剂的疗效与已知疗法相美.
- 这些抗体可以缩短治疗时间,减少淋巴激素的使用,并改善患者的接受度.
- 临床证据对辅助生殖和前列腺癌最为有力,在子宫内膜异位症,子宫纤维瘤,乳腺癌,良性前列腺增生和早期青春期有潜在的应用.
结论:
- GnRH 抗剂代表了阻断 GnRH 作用的重大进步.
- 它们在各种临床适应症中为GnRH激动剂提供了有希望的,有效的替代品.
- 进一步的临床证据支持它们的使用,特别是在辅助生殖和前列腺癌管理方面.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
相关概念视频
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Antidepressant Drugs: MAOIs and Other Agents
